Crosstalk between cancer cells and bone microenvironment in bone metastasis

被引:248
作者
Yoneda, T
Hiraga, T
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA
[2] Osaka Univ, Grad Sch Dent, Dept Biochem, Suita, Osaka 5650891, Japan
关键词
bone metastasis; breast cancer; osteoclasts; bone-stored growth factors; PTH-rP;
D O I
10.1016/j.bbrc.2004.11.070
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone, as well as lung and liver, is one of the most preferential metastatic target sites for cancers including breast, prostate, and lung cancers. Although the precise molecular mechanisms underlying this preference need to be elucidated, it appears that bone microenvironments possess unique biological features that enable circulating cancer cells to home, survive and proliferate, and destroy bone. In conjunction, cancers that develop bone metastases likely have the capacity to utilize these unique bone environments for colonization and bone destruction. This crosstalk between metastatic cancer cells and bone is critical to the development and progression of bone metastases. Disruption of this interaction will allow us to design mechanism-based effective and specific therapeutic interventions for bone metastases. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:679 / 687
页数:9
相关论文
共 71 条
[1]   Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells [J].
Adwan, H ;
Bäuerle, TJ ;
Berger, MR .
CANCER GENE THERAPY, 2004, 11 (02) :109-120
[2]   Laminin 5 β3 and γ 2 chains are frequently coexpressed in cancer cells [J].
Akimoto, S ;
Nakanishi, Y ;
Sakamoto, M ;
Kanai, Y ;
Hirohashi, S .
PATHOLOGY INTERNATIONAL, 2004, 54 (09) :688-692
[3]  
Arboleda MJ, 2003, CANCER RES, V63, P196
[4]  
BOYDE A, 1986, Scanning Electron Microscopy, P1537
[5]   PARATHYROID-HORMONE RELATED PROTEIN AND SKELETAL MORBIDITY IN BREAST-CANCER [J].
BUNDRED, NJ ;
WALKER, RA ;
RATCLIFFE, WA ;
WARWICK, J ;
MORRISON, JM ;
RATCLIFFE, JG .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :690-692
[6]   Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP [J].
Burton, DW ;
Geller, J ;
Yang, M ;
Jiang, P ;
Barken, I ;
Hastings, RH ;
Hoffman, RM ;
Deftos, LJ .
PROSTATE, 2005, 62 (03) :275-281
[7]   Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [J].
Choi, SJ ;
Oba, Y ;
Gazitt, Y ;
Alsina, M ;
Cruz, J ;
Anderson, J ;
Roodman, GD .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) :1833-1841
[8]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[9]  
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO
[10]  
2-Z